These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 7541709

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Androgen receptor status of lymph node metastases from prostate cancer.
    Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A.
    Prostate; 1996 Feb; 28(2):129-35. PubMed ID: 8604394
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Androgen receptor expression in clinically localized prostate cancer: immunohistochemistry study and literature review.
    Qiu YQ, Leuschner I, Braun PM.
    Asian J Androl; 2008 Nov; 10(6):855-63. PubMed ID: 18958349
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma.
    Takeda H, Akakura K, Masai M, Akimoto S, Yatani R, Shimazaki J.
    Cancer; 1996 Mar 01; 77(5):934-40. PubMed ID: 8608487
    [Abstract] [Full Text] [Related]

  • 8. The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis.
    Habib FK, Ross M, Bayne CW, Bollina P, Grigor K, Chapman K.
    Clin Cancer Res; 2003 May 01; 9(5):1815-9. PubMed ID: 12738739
    [Abstract] [Full Text] [Related]

  • 9. Metastases of prostate cancer express estrogen receptor-beta.
    Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, Ho SM, Vessella RL, Corey E.
    Urology; 2004 Oct 01; 64(4):814-20. PubMed ID: 15491740
    [Abstract] [Full Text] [Related]

  • 10. GnRH receptor and androgen receptor status and outcome of advanced prostate carcinomas.
    Szabó J, Bartók K, Krenács T, Szepesváry Z, Szende B.
    Anticancer Res; 2009 Feb 01; 29(2):681-4. PubMed ID: 19331222
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides.
    Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G, Klocker H.
    Cancer Gene Ther; 2000 Jul 01; 7(7):997-1007. PubMed ID: 10917202
    [Abstract] [Full Text] [Related]

  • 12. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
    Sweat SD, Pacelli A, Bergstralh EJ, Slezak JM, Cheng L, Bostwick DG.
    J Urol; 1999 Apr 01; 161(4):1233-7. PubMed ID: 10081876
    [Abstract] [Full Text] [Related]

  • 13. Heterogeneity of androgen receptor content in advanced prostate cancer.
    Magi-Galluzzi C, Xu X, Hlatky L, Hahnfeldt P, Kaplan I, Hsiao P, Chang C, Loda M.
    Mod Pathol; 1997 Aug 01; 10(8):839-45. PubMed ID: 9267828
    [Abstract] [Full Text] [Related]

  • 14. DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation.
    Alimirah F, Chen J, Basrawala Z, Xin H, Choubey D.
    FEBS Lett; 2006 Apr 17; 580(9):2294-300. PubMed ID: 16580667
    [Abstract] [Full Text] [Related]

  • 15. Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone.
    Alers JC, Krijtenburg PJ, Rosenberg C, Hop WC, Verkerk AM, Schröder FH, van der Kwast TH, Bosman FT, van Dekken H.
    Lab Invest; 1997 Nov 17; 77(5):437-48. PubMed ID: 9389787
    [Abstract] [Full Text] [Related]

  • 16. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
    Jackson KM, Frazier MC, Harris WB.
    Anticancer Res; 2007 Nov 17; 27(3B):1483-8. PubMed ID: 17595765
    [Abstract] [Full Text] [Related]

  • 17. Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma.
    Mohler JL, Chen Y, Hamil K, Hall SH, Cidlowski JA, Wilson EM, French FS, Sar M.
    Clin Cancer Res; 1996 May 17; 2(5):889-95. PubMed ID: 9816246
    [Abstract] [Full Text] [Related]

  • 18. Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone.
    Culig Z, Stober J, Gast A, Peterziel H, Hobisch A, Radmayr C, Hittmair A, Bartsch G, Cato AC, Klocker H.
    Cancer Detect Prev; 1996 May 17; 20(1):68-75. PubMed ID: 8907206
    [Abstract] [Full Text] [Related]

  • 19. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.
    Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z.
    Cancer Res; 1998 Oct 15; 58(20):4640-5. PubMed ID: 9788616
    [Abstract] [Full Text] [Related]

  • 20. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
    Zaia A, Fraizer GC, Piantanelli L, Saunders GF.
    Anticancer Res; 2001 Oct 15; 21(1A):1-10. PubMed ID: 11299720
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.